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A B S T R A C T   
Dissolving microneedle arrays (dMNAs) are promising devices for intradermal vaccine delivery. The aim of this 
study was to develop a reproducible fabrication method for dMNAs based on an automated nano-droplet 
dispensing system that minimizes antigen waste. First, a polymer formulation was selected to dispense suffi-
ciently small droplets (<18 nL) that can enter the microneedle cavities (base diameter 330 µm). Besides, three 
linear stages were assembled to align the dispenser with the cavities, and a vacuum chamber was designed to fill 
the cavities with dispensed droplets without entrapped air. Lastly, the dispenser and stages were incorporated to 
build a fully automated system. To examine the function of dMNAs as a vaccine carrier, ovalbumin was loaded in 
dMNAs by dispensing a mixture of ovalbumin and polymer formulation, followed by determining the ovalbumin 
loading and release into the skin. The results demonstrate that functional dMNAs which can deliver antigen into 
the skin were successfully fabricated via the automatic fabrication system, and hardly any antigen waste was 
encountered. Compared to the method that centrifuges the mould, it resulted in a 98.5% volume reduction of 
antigen/polymer solution and a day shorter production time. This system has potential for scale-up of 
manufacturing to an industrial scale.   
1. Introduction 
Intradermal administration of antigens is attractive for vaccination, 
because the skin is easily accessible and contains a large population of 
antigen-presenting cells (Engelke et al., 2015; Skobe and Detmar, 2000). 
Previous studies revealed that intradermal vaccination induces similar 
or higher levels of immune responses as compared to subcutaneous or 
intramuscular administration. Intradermal vaccination against Aujesz-
ky’s disease induced higher levels of CD8β+, CD3-CD8α+, and 
CD4-CD25+ T lymphocytes compared to intramuscular administration 
(Ferrari et al., 2011). Also, injection of muramyl dipeptide loaded 
ovalbumin microspheres through the intradermal route showed rela-
tively higher ovalbumin-specific IgG antibody immune response levels 
compared to the subcutaneous route (Puri et al., 2000). 
However, the stratum corneum, the outermost layer of the skin, 
which acts as a barrier to protect the body from its environment, also 
prevents vaccines from entering the skin. To overcome this barrier, 
specialized delivery devices have been developed, such as tattooing, 
ballistic guns, ultrasound-based devices, and microneedles (Kagan et al., 
2012; Kwan et al., 2015; Soto et al., 2017; Yildirim et al., 2018). Among 
various intradermal delivery devices, one of the most attractive ap-
proaches is the use of microneedles, because they deliver antigen and/or 
adjuvant intradermally, resulting in a sufficient immune response (e.g., 
ovalbumin-specific IgG titers, CD4+ and CD8+ T-cells) in a minimally 
invasive manner (van der Maaden et al., 2014). Different types of 
microneedle technologies have been developed, including hollow, solid 
coated, solid with patch, porous, and dissolvable. These microneedles 
are generally <1 mm in length. 
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So far, delivery of antigen using hollow (Du et al., 2017; Niu et al., 
2019), coated (Koutsonanos et al., 2009; Vrdoljak et al., 2012), porous 
(Stenberg et al., 2019), and dissolving (Sullivan et al., 2010) micro-
needles has shown to trigger efficient immune responses. Dissolving 
microneedles are of special interest, because the antigen in a dissolving 
microneedle array (dMNA) is generally more stable compared to a liquid 
vaccine (Edens et al., 2015; Poirier et al., 2017). Therefore, a cold chain 
might be avoided. This is beneficial especially in low-income countries 
since high transport costs for the cold chain limit their vaccine coverage 
(Humphreys, 2011; Ochieng et al., 2020; Stenberg et al., 2019; Thio 
et al., 2015; Wang et al., 2007). Moreover, compared to injectable 
lyophilized vaccine formulations, there is no need for reconstitution. 
dMNAs have additional advantages. First, since they dissolve upon 
administration, there is no sharp-waste or risk of re-use. Furthermore, 
self-administration of dMNAs may be possible, which reduces the need 
for trained medical staff. This can accommodate the demand for 
increasing vaccination in developing countries by increasing the access 
to vaccination for people (Shea et al., 2009). For these reasons, dMNAs 
are promising devices for intradermal vaccine delivery. 
dMNAs can be made of sugars or biodegradable polymers, such as 
carboxymethylcellulose (CMC) (J. W. Lee et al., 2011), hyaluronic acid 
(HA) (Kim et al., 2018), and polyvinyl alcohol (PVA) (Nguyen et al., 
2018). In the past decade, fabrication methods for dMNAs have shown 
considerable progress and diversity. The most common methods use 
centrifugation after casting the mixture of antigen and polymer into a 
mould (Lee et al., 2008; Leone et al., 2019). Even though this concept is 
simple, the most important drawback is huge antigen loss as the antigen 
is also present in the backplate of the microneedle array, which is not 
inserted in the skin. Since the antigen is the most expensive part of the 
vaccine, antigen in the backplate leads to a huge loss of doses, which 
makes dissolving microneedle technologies less useful in pandemic 
situations. 
To circumvent the antigen loss during the preparation of dMNAs, 
several methods have been investigated. The temperature and the vis-
cosity of maltose solution were manipulated to produce dMNAs by 
drawing lithography (Lee et al., 2011) and multi-layers of different 
payload solutions were casted across the mould (Raphael et al., 2010). A 
piezoelectric dispenser also helped to load the antigen only in the 
microneedle tips (Allen et al., 2016). 
In the present study, we engineered a novel automated nano-droplet 
dispensing system for the dMNA fabrication (automatic fabrication 
system). We demonstrate the step-by-step design from screening the 
most adequate polymer formulation, selecting a dispenser, building and 
integrating linear stages and designing a vacuum chamber, to fill a series 
of microneedle arrays. This novel automatic fabrication system resulted 
in a significant volume reduction (98.5%) of required polymer formu-
lations compared to the centrifugation method. The mechanical stability 
and dissolution of fabricated dMNAs via the automatic fabrication sys-
tem was investigated through ex vivo human skin penetration studies 
andmicroneedle dissolution test. The potential use of dMNAs for vacci-
nation purposes was evaluated by delivering the model antigen oval-
bumin into ex vivo human skin and analysing the loaded and delivered 
amount of ovalbumin. 
2. Materials and methods 
2.1. Materials 
SYLGARD 184 base silicone elastomer and curing agent silicone 
elastomer were purchased from Dow Corning (Midland, MI, USA). Pol-
yvinylpyrrolidone (PVP, Mw 40 kDa), poly(ethylene glycol) (PEG, mo-
lecular weight 400 Da), PVA (Mw 9–10 kDa, 80% hydrolysed), CMC 
(low viscosity), gelatin and trypan blue solution 0.4% (w/v) were pur-
chased from Millipore Sigma (Zwijndrecht, The Netherlands). Sodium 
hyaluronate (HA, average Mw 10 kDa, 20 kDa, and 100 kDa) was pur-
chased from Lifecore Biomedical (Chaska, MN, USA). 
Vinylpolysiloxanes A-silicone (Elite Double 32) was from the Zhermack 
Group (Badia Polesine, Italy) and epoxy glue was from by Bison Inter-
national B.V. (Goes, The Netherlands). Tape (packing tape poly-
propylene, transparent) for stripping skin was purchased from Staples 
and ovalbumin-Alexa Fluor™ 647 conjugate was purchased from 
Thermo Fisher (The Netherlands). Silicon microneedle arrays were 
kindly provided by Tyndall National Institute (Cork, Ireland). This sili-
con microneedle array has nine (3 × 3) of 500 µm long microneedles 
with a base diameter of 330 µm on a backplate of 5 × 5 mm2, and be-
tween each microneedle is a spacing of 1.75 mm. Three linear stages 
(two of M− 403.4DG and one of M− 403.2DG) were purchased from 
Physik Instrumente Benelux B.V. (The Netherlands) and a PipeJet® 
Nanodispenser was purchased from BioFluidix GmbH (Germany). A 
microscope camera (USB microscope 2 MP digital zoom) was purchased 
from Toolcraft. 
For SDS PAGE, sample buffer (#1610737), 4–20% Mini-PROTEAN 
TGX Precast protein gels (#4561094), Tris/glycine/SDS running 
buffer (#1610732), Coomassie Brilliant Blue R-250 staining solution 
(#1610436) were purchased from Bio-Rad (Netherlands). 
2.2. Polymer screening for the automatic fabrication system 
2.2.1. Design of PMMA master structure and PDMS mould fabrication 
The dMNA fabrication started from a polymethylmethacrylate 
(PMMA) master structure which was made by the Fine Mechanical 
Department (FMD) at Leiden University. As shown in Fig. 1, the PMMA 
master structure has nine pedestals (3x3) and the surface area of each 
pedestal is 5x5 mm2. On top of each pedestal, a silicon microneedle 
array was attached. A polydimethylsiloxane (PDMS) mould was pre-
pared from this PMMA master structure as previously described (Leone 
et al., 2019). 
2.2.2. Fabrication of dMNAs using a centrifugation method 
In order to screen the most suitable polymer formulation in terms of 
sharpness, penetration efficiency, dissolution rate, and viscosity to be 
used for the automatic fabrication system, first dMNAs were fabricated 
by using a modified centrifugation method which has previously been 
developed in our group (Leone et al., 2019). Among widely used 
biodegradable polymers for dMNAs fabrication, five different polymer 
candidates with various concentration and molecular weights were 
chosen for the polymer screening (Table S1): PVP/PEG, PVA, HA, CMC, 
and gelatin (J. W. Lee et al., 2011; Leone et al., 2018a; Pei et al., 2018; 
Wang et al., 2018). Solid polymer was added to 10 mM phosphate buffer 
(PB, pH 7.4, prepared with 7.7 mM Na2HPO4 and 2.3 mM NaH2PO4), 
and PEG was added only to PVP at a 5.6% (w/w) concentration to 
improve the rigidity and the flexibility of PVP-containing dMNAs (Dillon 
et al., 2017; Quinn et al., 2015). The polymer in PB was shaken (IKA 
Vibrax VXR Basic, 1000 RPM) at 37 ◦C overnight to ensure homoge-
neous mixing of the different polymer formulations. Only HA solutions 
were shaken at 4 ◦C because of their poor thermal stability (Caspersen 
et al., 2014). 
The polymer concentration of each formulation was selected based 
on the ease of fabrication and the rigidity of produced dMNAs. Too high 
or too low polymer concentrations were excluded from further investi-
gation and were defined as follows; Too high concentration resulted in 
too high viscosity to cast the formulation into a PDMS mould, and too 
low concentration produced too brittle dMNAs to handle. The highest 
viscosity that we casted to the mould was 429 cP with 10% (w/v) HA 
100 kDa, and the lowest viscosity was 6.64 cP with 3.25% (w/v) PVP/ 
PEG (17.8:1 wt ratio). 
To fill the microneedle cavities of the PDMS mould, the polymer 
formulations were cast into the PDMS moulds and subsequently 
centrifuged (Beckman Coulter Allegra X12R Indianapolis, IN, USA) for 3 
h at 25 ◦C and 11,400 g. Only 40% (w/v) gelatin was centrifuged at 
37 ◦C to facilitate the filling of microneedle cavities, as the viscosity was 
too high at low temperature. The centrifuged mould was placed in a 
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37 ◦C oven and dried overnight. 
The following day, silicone backplates were prepared from vinyl-
polysiloxane and epoxy glue and applied onto each array as previously 
reported (Leone et al., 2019). The epoxy glue facilitates the demoulding 
of dMNAs from the PDMS mould. After removal, 3x3 dMNAs were cut 
into individual arrays and stored in a desiccator with silica-gel beads at 
room temperature (RT) until use. The shape and sharpness of the 
microneedles and the absence of air bubbles in the microneedles were 
investigated by using a brightfield microscope (Stemi 2000-C, Carl Zeiss 
Microscopy GmbH, Göttingen, Germany). 
2.2.3. Skin penetration test in ex vivo human skin 
The mechanical strength and sharpness of dMNAs fabricated via the 
centrifugation method were assessed by performing a skin penetration 
test. Human abdominal skin was collected from a local hospital after 
cosmetic surgery. Excess fat was removed, and the skin was stored at 
− 80 ◦C until use. Prior to use, the skin was thawed at 37 ◦C for an hour, 
and subsequently stretched on parafilm-covered Styrofoam. To remove 
the sebum, the skin was cleaned by wiping it with 70% ethanol. 
An impact-insertion applicator in conjunction with a microneedle 
applicator controller (uPRAX Microsolutions B.V., Delft, The 
Netherlands) was used to pierce the skin with a reproducible impact 
velocity (65 ± 1 cm/s) (Leone et al., 2018b). By using the applicator, a 
dMNA was applied on the skin and removed after one second. Next, 75 
µL of 0.4% (w/v) trypan blue was dropped on the site of microneedle- 
treated skin. The trypan blue was removed from the skin after 45 min, 
and the stratum corneum was removed by around 10 times of tape 
stripping in alternating direction. Finally, the skin was photographed 
and the number of blue spots, which indicate the number of penetrated 
microneedles, were analysed. The penetration studies for each dMNA 
formulation were carried out in quadruplicate. The penetration effi-
ciency was calculated by dividing the number of penetrations (blue 
spots) by nine, the total number of microneedles in one array. 
2.2.4. Microneedle dissolution test in ex vivo human skin 
For vaccination, a rapid dissolution of the microneedles (preferably 
<20 min) is desired to limit the application time of dMNAs. To this end, 
we aimed to screen the polymer formulation that showed the fastest 
dissolution by displaying the shortest remaining height of microneedles 
after dissolution. Thereby, a microneedle dissolution test was executed 
and the remaining height of dissolved microneedles at the same time 
period was measured. dMNAs were applied onto the skin as described in 
Section 2.2.3, and the microneedles stayed in the skin for 5 min. The 
shape of the removed microneedle was visualized by using a brightfield 
microscope, and the remaining height of microneedles was measured. 
Three microneedles were tested for each formulation. 
2.2.5. Viscosity 
The next step after polymer screening based on the skin penetration 
study and microneedle dissolution test, was selecting the optimal poly-
mer concentration to produce nano-droplets using the dispenser to fill 
the microneedle cavities of the mould. As the dispenser can only be used 
when the polymer formulations have a viscosity below 50 mPa.s, it is 
important to determine the viscosity of the polymer formulation. 
Therefore, the viscosity for various concentrations of the selected 
polymer were measured by using a viscometer (Brookfield Ametek, 
DV2T). The measurement was performed for 60 s at RT and 5 RPM in 
triplicate. The device was set at a shear rate and shear stress of 0.122 (1/ 
s) and 0.04 (dyn/cm2), respectively. 
2.3. Automatic fabrication system 
To reduce the loss of antigen-containing formulation, an automatic 
fabrication system was developed for loading it exclusively into the 
microneedle cavities. This system was composed of five main compo-
nents: dispenser with its holder, vacuum chamber, microscope camera, 
linear stages, and a vacuum pump. 
First, the dispenser (Fig. 2a) was selected based on the size of 
droplets it can produce. To this end, a PipeJet® Nanodispenser was 
selected, which can generate droplets as small as 1.2 nL (132 µm of 
diameter) and thus fits easily to a single microneedle cavity (volume 14 
nL, base diameter 330 µm). The dispenser was fixed on a holder 
(Fig. 2b). 
Next, a digital microscope camera (Fig. 2c) was installed on the 
aluminium bar (Fig. 2d) and positioned under the PDMS mould to 
visualize the filling of the microneedle cavities. Then, three linear stages 
(Fig. 2e) were assembled to carry the PDMS mould in the x-, y-, and z- 
directions. On the z-stage, a vacuum chamber (Fig. 2f) which was con-
nected to a vacuum pump (Fig. 2g) was fixed. This vacuum chamber was 
designed to support the PDMS mould (Fig. 2h) and also remove the 
entrapped air in the microneedle cavities. Lastly, the dispenser and three 
linear stages were incorporated in a software, Python (v3.8). 
The process for dMNA fabrication via the automatic fabrication 
system is as follows. First, the PDMS mould is placed on the vacuum 
chamber and the vacuum pump is turned on. Three linear stages give 
movement to the PDMS mould, and the first microneedle cavity is 
aligned with the dispenser nozzle. To confirm this alignment, the 







Fig. 1. PDMS mould fabrication process. Nine silicon arrays were attached on the pedestals of a PMMA master structure (left). A PDMS solution was poured into the 
master structure followed by overnight curing (right bottom). The resulting PDMS mould contains nine arrays and each array has nine individual microneedles 
(right top). 
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and monitored by using the integrated microscope camera. Next, each 
microneedle cavity is sequentially filled with nano-droplets, while the 
low-pressure is applied to the PDMS mould. Filling of the microneedle 
cavities is repeated until the desired volume has been loaded into the 
individual microneedle cavities of the PDMS mould. After filling of all 
nine microneedle arrays, epoxy glue is applied followed by overnight 
drying. The next day, dMNAs are carefully separated from the PDMS 
mould. The detailed set-ups of each component in the automatic fabri-
cation system are described below. 
2.3.1. Dispensing droplets into the microneedle cavities of the PDMS mould 
As a result of the polymer formulations screening (see Section 2.2 
and results Section 3.1), 6.5% (w/v) PVP/PEG was selected to be used 
for the automatic fabrication system. In order to visualize the dispensing 
process clearly, initially 0.1% (w/v) rhodamine B dye was added to 6.5% 
(w/v) PVP/PEG. The dispenser was connected to a 1000 µL reservoir 
through 8–9 cm of a Teflon tube (inner diameter 1.6 mm, outer diameter 
3.2 mm). Air bubbles in the tube were removed by tapping. 
To optimize the dispensing process (before the dispenser holder and 
the vacuum chamber were designed), the dispenser was fixed by a ring 
stand and the mould was placed on the elevated flat surface. Each 
microneedle cavity was aligned with the dispenser nozzle manually by 
hand, and the dispensing process was monitored though the microscope 
camera. 
2.3.2. Movement of linear stages 
In order to position microneedle cavities of the PDMS mould, the 
automatic fabrication system requires three linear stages: x-, y-, z-stages 
(Fig. 2e). Two long linear stages (M− 403.4DG) were used for the x- and 
y-stages and one short linear stage (M− 403.2DG) was used for the z- 
stage. Each stage was connected to a direct-current gear motor 
controller and selected based on the accuracy of the motor’s movement. 
The minimum incremental motion of the motor was 0.2 µm. Considering 
the distance between each microneedle cavity was 1.75 mm, 0.2 µm was 
a high enough resolution to obtain an accurate alignment of each 
microneedle cavity with the dispenser nozzle. 
The y-stage was installed perpendicularly to the x-stage, and the z- 
stage was installed on the y-stage perpendicularly to the x-y plane. 
Before incorporating the dispenser and stages using Python, the move-
ment of stages to the desired position was controlled with its own soft-
ware, PIMikroMove (v2.31.1.8). The PDMS mould can be moved 
between 0 and 100 cm for the x- and y-directions and between 0 and 50 
cm for the z-direction. 
2.3.3. Dispenser holder and microscope camera 
To fix the dispenser at a predetermined position on the stage, a 
dispenser holder was designed by using SolidWorks (SOLIDWORKS 
Student Design Kit (2017–2018)) and 3D-printed (by FMD at Leiden 
University) with PMMA. Even a little movement of the dispenser can 
misalign the dispenser nozzle with the microneedle cavities. In order to 
prevent misalignment, the groove of the dispenser holder (Fig. 2b) was 
designed in such a way that it can hold the dispenser tightly with a 
screw. Both the dispenser holder and the microscope camera (Fig. 2c) 
were screwed on an aluminium bar (Fig. 2d), which was installed on the 
x-stage. The microscope camera was controlled via MicroCapturePlus 
(v3.1). 
2.3.4. Filling the microneedle cavities and design of the vacuum chamber 
When air gets entrapped into the microneedle cavities, it hinders 
drawing down the polymer formulation to the tip, which results in 
diminishing the mechanical properties and sharpness of the micro-
needles. In order to avoid and/or remove air from the microneedle 
cavities, four different methods were assessed.  
1) 0.01% (w/v) or 0.1% (w/v) polysorbate 80 (PS80) was added to 
6.5% (w/v) PVP/PEG, the selected formulation, and dispensed into 
the microneedle cavities. The PS80 was expected to reduce the sur-
face tension of the polymer solution and make it reach the tip. 
Dispensing was performed for seven cycles, and one cycle consists of 
filling all 81 microneedle cavities once. 
Fig. 2. Schematic representation of the automatic fabrication system for dMNA fabrication. The automatic fabrication system consists of the following equipment: (a) 
dispenser, (b) dispenser holder, (c) digital microscope camera, (d) aluminium bar, (e) linear stages, (f) vacuum chamber, and (g) vacuum pump. (h) The PDMS mould 
is placed on top of the vacuum chamber. Both the dispenser and the stages are operated by software, Python. 
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2) A degassing step was added after each dispensing cycle. For 
degassing, the mould was placed in the vacuum vessel (100 mbar) for 
different time points: 30 sec, 2 min, 3 min, and 5 min. The vacuum 
was expected to drive out the air from the microneedle cavities.  
3) The mould was centrifuged (11,400 g) after each dispensing cycle for 
1 min, 2 min, and 5 min. The centrifugal force was supposed to 
remove the air by rising it up to the surface as it did during the 
fabrication via the original centrifugation method.  
4) The low-pressure was applied to PDMS moulds of two different 
thicknesses. As the PDMS mould is porous, the applied low-pressure 
can suck the air from the microneedle cavities. In order to apply the 
low-pressure to the bottom side of the PDMS mould, the mould was 
placed on the designed vacuum chamber (Fig. 3), such that each 
array of the PDMS mould could be placed on a square hole of the 
vacuum chamber. In this way, the low-pressure could be applied 
directly to the microneedle cavities. The transparent vacuum 
chamber was fixed on the z-stage and positioned between the 
dispenser and the microscope camera (see Fig. 2). Hence, the camera 
can monitor the dispensing process by imaging the PDMS mould. 
The intensity of the low-pressure and the thickness of the PDMS 
mould can affect the air removal efficiency in the microneedle cavities. 
In order to investigate the optimal conditions for removing the air, both 
the intensity of the low-pressure and the thickness of the PDMS mould 
were varied, and the number of intact microneedles was counted after 
fabrication. 
The thickness of the PDMS mould was either 8 mm or 4.5 mm 
(Fig. 4), while three pressures were applied: 100 mbar, 50 mbar, and 8 
mbar. This allowed us to determine the minimum pressure needed to 
produce air-free microneedles. After fabrication of dMNAs, the fraction 
of intact microneedles was calculated (n = 3). For this, the number of 
intact microneedles was divided by 81 being the total number of 
microneedles produced in one mould. 
2.3.5. Automatic fabrication of dMNAs 
To build a fully automated system, the dispenser and linear stages 
were incorporated and controlled by using Python. The filling process 
starts from lifting up the PDMS mould using the z-stage, so that the array 
can reach the dispenser nozzle as close as possible. The x- and y-stages 
can shift their positions from 0 to 100 cm, and each microneedle cavity is 
aligned with the dispenser nozzle by designating the position of the 
microneedle cavity through the software. For example, if we want to 
move the PDMS mould to the middle of each stage, we need to input its 
desired position as (50, 50). The position of the first microneedle cavity 
is set as (a, b) and the position of the additional 80 microneedle cavities 
is allocated by adding the distance (x, y) from the first microneedle 
cavity to the microneedle cavity of interest (a + x, b + y). 
Based on the results of dispenser optimization (Section 3.2.1), the 
droplet size was set to 1.5 nL. After alignment, 10 shots of a 1.5 nL 
droplet entered the first microneedle cavity. Then, the x-, y-stages shift 
the PDMS mould again and align the next microneedle cavity with the 
dispenser. 
In order to determine the minimum number of dispensing cycles for 
air-free microneedles, the number of cycles was varied from 5 to 10. 
After dispensing process, epoxy glue was applied on dMNAs, and dMNAs 
were carefully removed after drying, as described in Section 2.2.2. 
2.3.6. Analysis of the integrity of automatically fabricated dMNAs 
The shape of the automatically fabricated dMNAs was analysed by 
using a brightfield microscope. In order to monitor that the micro-
needles were completely filled without any air bubbles, we also visual-
ized the cross-section of microneedles using a scanning electron 
microscope (SEM, Nova NanoSEM-200, FEI, Hillsboro, OR, USA). The 
microneedle was cut at 360 µm height from the base by using a micro-
tome (Leica RM2235, Germany) and the SEM was set at an acceleration 
voltage of 2 kV, a working distance of 10.1 mm, and a current of 13 pA. 
Furthermore, the distribution of polymer with rhodamine B dye in the 
dMNA was visualized by using a fluorescence microscope (Zeiss Imager 
D2, camera AxioCam MRm, light source HXP120V, Carl Zeiss Micro-
scopyGmbH, Göttingen, Germany). 
2.4. Automatic fabrication of ovalbumin loaded dMNAs 
In order to demonstrate the function of dMNAs as an antigen carrier, 
AF647 labelled ovalbumin was loaded in dMNAs as a model antigen. As 
ovalbumin increased the viscosity, the total concentration of PVP/PEG 
together with ovalbumin was decreased from 6.5% (w/v) to 5% (w/v) to 
lower the viscosity and increase the dissolution rate. The ratios between 
PVP/PEG and ovalbumin were varied, while keeping the total concen-
tration the same: 4:1 (4% (w/v) PVP/PEG and 1% (w/v) ovalbumin) and 
1:1 (2.5% (w/v) PVP/PEG and 2.5% (w/v) ovalbumin). After the 
mixture was shaken overnight at 4 ◦C, dMNAs were fabricated as 
described in Section 2.3.5 with 10 dispensing cycles. The skin penetra-
tion study and microneedle dissolution test were carried out as described 
in Sections 2.2.3 and 2.2.4, respectively. The penetrated skin and re-
sidual microneedles after dissolution were analysed by using brightfield 
and fluorescence microscope. 
2.5. Loading efficiency and released amount of ovalbumin 
To determine the loading efficiency of ovalbumin in the dMNAs, 
AF647-ovalbumin loaded dMNAs (n = 3) were added to 300 µL PB and 
shaken overnight at 4 ◦C. On the next day, the fluorescence intensity of 
the dMNAs dissolved in PB and the same volume (1.35 µL) of dispensing 
solutions (AF647-ovalbumin and PVP/PEG mixture, n = 3) was 
measured by using a Tecan Infinite M1000 plate reader (Männedorf, 
Switzerland) with an excitation wavelength of 650 nm and an emission 
wavelength of 668 nm. The loading efficiency was calculated as a ratio 
of fluorescence intensity of AF647-ovalbumin in dMNAs and in 
dispensing solutions. 
Fig. 3. Design of the vacuum chamber. The PDMS mould is placed on (a) the top of the vacuum chamber. The empty space under (b) the PDMS mould serves as (c) 
the vacuum chamber. The top and bottom of the vacuum chamber are sealed with the PDMS mould and (d) a transparent panel, respectively. The vacuum chamber is 
connected to the vacuum pump through (e) the hose outlet. 
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To determine the delivered amount of AF647-ovalbumin from 
dMNAs to the skin, the dMNAs before and after dissolution were added 
to 300 µL PB (n = 3) and shaken overnight at 4 ◦C. The fluorescence 
intensity of AF647-ovalbumin in both solutions was determined. To 
determine the amount of ovalbumin dissolved, the fluorescent intensity 
value after dissolution of the dMNAs was subtracted from that of the 
dMNAs before the dissolution test. 
2.6. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS- 
PAGE) 
The stability of ovalbumin in the dMNA was characterized with SDS- 
PAGE. The ovalbumin loaded dMNA was added to 300 µL of PB and 
shaken overnight at 4 ◦C. Then a sample was prepared by mixing 25 µL 
of dMNA dissolved in PB with an equal volume of sample buffer (65.8 
mM Tris-HCl pH 6.8, 26.3% (w/v) glycerol, 2.1% SDS, 0.01% bromo-
phenol blue, 5% (v/v) β-mercaptoethanol). This mixture was loaded into 
a 4–20% polyacrylamide gel. Electrophoresis was performed in Tris/ 
glycine/SDS running buffer under constant voltage at 150 V for 60 min. 
The gel was stained by using Coomassie Brilliant Blue R-250 staining 
solution for 15 min and destained in water:methanol:acetic acid solution 
(50:40:10 v/v/v) for an hour. Quantification of stained protein bands 
was performed by using calibrated densitometer (Bio-Rad GS-800, 
Netherlands) and bands were analysed with Image Lab (v 6.1). 
2.7. Statistical analysis 
The remaining height of dissolved microneedles were analysed by 
using one way ANOVA. The level of significance was set at p < 0.01. 
3. Results 
3.1. Centrifugation-based fabrication method and selection of polymer 
formulation 
3.1.1. dMNA fabrication using the centrifugation method 
dMNAs were successfully fabricated using the centrifugation method 
with five different polymers and various concentrations, as listed in 
Table S1. The microscopic images showed that each microneedle had a 
symmetrical conical shape with a sharp tip (Fig. 5a and b). Some poly-
mer formulations were discarded based on difficulties during the 
fabrication process or improper mechanical strength after fabrication. 
On the one hand, too low concentrated polymer solutions (e.g., 3.25% 
(w/v) PVP/PEG) resulted in too brittle dMNAs (Fig. 5c) to carry out the 
skin penetration test. On the other hand, too high polymer concentra-
tions (e.g., 50% (w/v) PVA) resulted in too viscous solutions to cast onto 
the mould. Therefore, 3.25% (w/v) PVP/PEG, 10% (w/v) 5 kDa HA, 
50% (w/v) PVA, and 30% (w/v) CMC solutions were excluded. With all 
polymer formulations (except those excluded with too high/low poly-
mer concentrations, as defined in Section 2.2.2), dMNAs were fabricated 
and used for further studies. In the fluorescence microscopic image of 
the fabricated dMNA (Fig. 5d), the red part in the array indicates that 
PVP/PEG with fluorescent dye (rhodamine B) is spread over the array. 
3.1.2. Skin penetration test in ex vivo human skin 
To determine whether the selected dMNAs (fabricated via the 
centrifugation method) can penetrate the skin, a skin penetration study 
was performed. The studies showed that all selected dMNAs displayed 
excellent penetration efficiencies in human abdominal skin (Fig. S1 and 
Table 1). In total 9 out of 15 dMNAs from the various polymer formu-
lations displayed 100% penetration efficiency (n = 4). The lowest 
penetration efficiency (91.7%) was shown for 40% (w/v) gelatin 
dMNAs, indicating that at least 8 out of 9 microneedles in one array 
could penetrate the skin. 
3.1.3. Microneedle dissolution test in ex vivo human skin 
Since fabricated dMNAs from each polymer formulation demon-
strated sufficient mechanical strength and over 90% penetration effi-
ciency in the skin penetration test, the next step of screening the polymer 
formulation was based on a microneedle dissolution test. 
Residual microneedles after 5 min dissolution were analysed by 
using a brightfield microscope (Fig. S2). From the microscopic image, 
the leftover height of microneedles from each formulation was measured 
and provided in Fig. 6. Among all microneedles, microneedles prepared 
Fig. 4. Different thicknesses of PDMS moulds. PDMS moulds are shown with a thickness of (a) 8 mm and (b) 4.5 mm. In both designs, (c) the distance from the upper 
surface of the mould to the tip of the microneedles is equal to 2.5 mm. Therefore, the thickness of moulds is defined as (d) the distance from the tip of the 
microneedles to the bottom surface of the mould. 
Fig. 5. dMNAs fabricated by using the centrifugation method. Brightfield microscopic images of representative examples of polymer formulations that resulted in 
sharp and strong conical dMNAs made of (a) 6.5% (w/v) PVP/PEG and (b) 10% (w/v) PVA. (c) Brittle dMNA made of 3.25% (w/v) PVP/PEG. (d) Fluorescence 
microscopic image of 6.5% (w/v) PVP/PEG dMNA. 
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with 6.5% (w/v) PVP/PEG showed the shortest average remaining 
height as 43.8 µm (8.8% of full height). In contrast, microneedles pre-
pared from 40% (w/v) gelatin hardly dissolved and showed the tallest 
residual height as 334.9 µm (67.0% of full height). 
In general, the graph clearly shows that the residual height of the 
microneedles decreased together with the molecular weights or con-
centration within the same kind of polymer. Based on the results of the 
microneedle dissolution test, PVP/PEG was selected for further studies. 
3.1.4. Viscosity 
As the dispenser can handle formulations with a viscosity up to 50 
mPa.s, the viscosity of 6.5–52% (w/v) PVP/PEG formulations were 
measured in order to select the proper concentrations of PVP/PEG to be 
used in the dispenser. With increasing the concentration of PVP/PEG, 
the viscosity also increased from 7.8 mPa.s to 96.2 mPa.s (Fig. 7). From 
this, it is clear that concentrations ranging from 6.5% (w/v) to 26% (w/ 
v) were adequate for the dispenser, while the 52% (w/v) PVP/PEG so-
lution was out of the working range. Since a lower polymer concentra-
tion showed a faster dissolution (see Section 3.1.3), a PVP/PEG 
concentration of 6.5% (w/v) was selected for the development of an 
automatic fabrication system. 
3.2. Automatic fabrication of dMNAs 
3.2.1. Optimization of nano-dispenser 
Prior to dispensing droplets with the selected polymer solution, 
optimization of the nano-dispenser was required. According to the 
specifications of the dispenser, the smallest droplet volume that the 
dispenser can produce is 1.2 nL (diameter 132 µm). As the entrance 
diameter of the microneedle cavities is 330 µm, assuming that the 
droplets are spherical, droplets with a volume of up to 18.8 nL (diameter 
330 µm) can enter the microneedle cavities. However, we observed that 
smaller droplets allowed better tip filling, whereas larger droplets easily 
got stuck at the tip entrance and resulted in a loss of polymer solution. 
Therefore, it was decided to dispense 10 shots of 1.5 nL droplets at a 
frequency of 10 Hz to fill each microneedle cavity. 
After dispensing 10 droplets, the water in dispensed polymer solu-
tion evaporated and the microneedle cavity created space for the next 
dispensing cycle, while the dispenser filled the other 80 microneedle 
cavities. Sequential dispensing of 10 drops into all 81 cavities of 9 
microneedle arrays is referred to as one dispensing cycle. As the number 
of dispensing cycles increased, the cumulative amount of polymer in the 
microneedle cavities also increased (Fig. 8a to c). After seven cycles, the 
microneedle cavities were filled and no more polymer solution could be 
dispensed, since the entrance of the cavities was blocked (Fig. 8c). As no 
automatic moving system was introduced yet, these studies were made 
by manual displacement of the PDMS mould. 
As a result of filling, the dispensed droplets of seven cycles failed to 
display a sharp tip (Fig. 8d) and it suggested the entrapment of air in the 
microneedle cavities. Possibly, the hydrophilic-hydrophobic interface 
between the polymer solution and the PDMS mould created this air. 
Therefore, filling of the microneedle cavities needed to be improved to 
avoid the air entrapment in the microneedle cavities. 
3.2.2. Filling the microneedle cavities 
In order to prevent and/or remove the air in the microneedle cav-
ities, four different methods were investigated.  
1) A concentration of 0.01% (w/v) or 0.1% (w/v) PS80 was added to 
6.5% (w/v) PVP/PEG to lower the surface tension of the solution. 
Table 1 
List of polymer formulations and penetration efficiency of dMNAs. The selection 
of polymer formulations was based on their viscosity during the fabrication 
process and the mechanical properties (i.e., rigidity) of dMNAs after fabrication. 
The discarded polymer formulations are listed in Table S1. The data was pre-
sented as mean ± SD (n = 4).   
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Fig. 6. Residual height of microneedles after 5 min dissolution in ex vivo 
human skin. The higher bar shows more residual height of microneedles after 
dissolution in the same time period (n = 3, three individual microneedles, Error 
bars = SD). 
Fig. 7. Viscosity of PVP/PEG formulations. The viscosity of PVP/PEG polymer 
(17.8:1 wt ratio) formulations increases as the concentration of the polymers 
increases. The viscosity was measured by using a viscometer at RT and 5 RPM 
(Brookfield Ametek DV2T, USA). Error bars represent standard deviations. (n =
3, triplicate preparations measured once). 
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However, adding PS80 to the polymer solution did not result in sharp 
tips of the microneedles, even at a PS80 concentration of 0.1% 
(Fig. 9a).  
2) After each dispensing cycle, microneedle arrays were moved to a 
vacuum vessel for degassing at 100 mbar. The degassing step drew 
down the polymer solution closer to the tip and extended the height 
of microneedles, however, it failed to fill the microneedle cavities 
completely even after degassing for 5 min (Fig. 9b).  
3) A centrifugation step was performed after each dispensing cycle. This 
method showed better tip formation compared to the previous two 
methods. However, even though the polymer formulation reached to 
the tip of microneedles after 2 min of centrifugation, air bubbles 
were still trapped in the microneedles. To remove these air bubbles, a 
longer centrifugation time of 5 min was required (Fig. 9c). Compared 
to the initial centrifugation method, adding a centrifugation step 
after each dispensing cycle reduced the centrifugation time from 3 h 
to 5 min. However, it requires seven centrifugation steps, because the 
dispensing cycles were executed seven times. Besides, it cannot 
construct a fully automated system as it demands to move the mould 
from the automatic system to the centrifuge after each dispensing 
cycle.  
4) Low-pressure was applied to PDMS moulds of different thicknesses 
during the dispensing process. Three different pressures of 100 mbar, 
50 mbar, and 8 mbar were applied to PDMS moulds with a thickness 
of 8 mm and 4.5 mm (see Fig. 4). The low-pressure was delivered to 
the microneedle cavities through a specially designed vacuum 
chamber (Section 2.3.4). 
When the same pressure was applied, more intact microneedles were 
observed with the 4.5 mm thickness mould compared to the 8 mm 
thickness mould (Table 2). Fig. 9d shows that 8 mbar with 4.5 mm 
thickness of PDMS mould was sufficiently strong so that the entrapped 
air was removed from the microneedle cavities. In conclusion, applying 
a low-pressure via the vacuum chamber was the most successful method 
among four different approaches for air removal from the microneedle 
cavities. For further experiments, 8 mbar of vacuum and 4.5 mm 
thickness of PDMS mould were used. 
Microneedles were also analysed individually by SEM after cutting it 
with a microtome in order to confirm that there was no air bubble 
entrapped. The appearance of the cross-sections in the images confirmed 
that no air bubbles were entrapped in the fabricated microneedles 
(Fig. 10a and b). 
Next, operations of the dispenser and stages were successfully 
incorporated using Python. Dispensing droplets and positioning of the 
PDMS mould were alternately repeated until completing the designated 
number of cycles. 
3.3. Comparison of fabricated dMNAs by the centrifugation method and 
the automatic fabrication system 
After automatically fabricating dMNAs, the distribution of polymer 
formulation was compared to centrifugally prepared dMNAs. For the 
automatically fabricated dMNA, the fluorescent dye, which was added 
to the polymer solution, was located only in the microneedles (Fig. 10c 
and d). In contrast, the fluorescent dye spread over the array including 
Fig. 8. Dispensed nano-droplets into the microneedle cavities and a removed microneedle from the mould after dispensing. Brightfield microscopic images of 
microneedle cavities after the (a) first (b) fifth and (c) seventh cycle. (d) The absence of microneedle tip indicates the presence of the air in the microneedle cavity 
(scale bar = 300 µm). 
Fig. 9. Fabricated 6.5% (w/v) PVP/PEG microneedles by using four different methods to fill the microneedle cavities completely. (a) Adding 0.1% (w/v) PS80 and 
(b) performing a degassing step for 5 min after each dispensing cycle drew down the solution closer to the tip of microneedles. (c) Centrifugation step for 5 min was 
sufficient to fabricate a sharp microneedle without air. (d) Applying the low-pressure during the dispensing cycle also successfully removed the air from the 
microneedle. (scale bar = 300 µm). 
Table 2 
Percentage of intact microneedles as function of PDMS mould thickness and low- 
pressure. When pressure decreased and PDMS mould thickness decreased, the 
number of intact microneedles increased. (n = 3, triplicate preparations 
measured once).  
Vacuum 
pressure 
8 mm PDMS 4.5 mm PDMS 
100 mbar 35.4% intact microneedles (SD 
= 4.33%) 
75.3% intact microneedles (SD 
= 1.23%) 
50 mbar 56.4% intact microneedles (SD 
= 0.71%) 
90.1% intact microneedles (SD 
= 1.23%) 
8 mbar 70.0% intact microneedles (SD 
= 1.43%) 
97.1% intact microneedles (SD 
= 0.71%)  
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the backplate for the dMNA fabricated via the centrifugation method 
(Fig. 5d). This indicates that substantial less antigen containing formu-
lation is needed for the dispensed method compared to the centrifuged 
method. As the automatic fabrication required 10 dispensing cycles to 
fill the microneedle cavities completely, it demanded only 1.35 µL (1.5 
nL × 10 droplets × 10 cycles × 9 MNs) of 6.5% PVP/PEG solution to 
fabricate one dMNA by the dispensed method, while the centrifugation 
method needed 90 µL of minimum volume. 
In the skin penetration test and microneedle dissolution test, the 
automatically fabricated dMNAs showed similar results to dMNAs 
fabricated via the centrifugation method with 100 ± 0% penetration 
efficiency and 58.1 µm (11.6% of full height) of remaining height within 
5 min (data not shown). 
3.4. Ovalbumin loaded dMNAs and delivery into the skin 
In order to demonstrate that antigens can be incorporated in the 
automatically fabricated dMNAs while maintaining the dMNA proper-
ties, fluorescent dye (AF647)-labelled ovalbumin was loaded in dMNAs 
as a model antigen. AF647-ovalbumin loaded in dMNAs with a 4:1 ratio 
of PVP/PEG:AF647-ovalbumin resulted in a sharp microneedle shape, as 
shown in Fig. 11a. 
AF647-ovalbumin loaded dMNAs showed 100 ± 0% penetration 
efficiency (n = 4, Fig. 11b), and the fluorescence in the penetrated skin 
indicated that AF647-ovalbumin in the microneedle was successfully 
delivered into the skin (Fig. 11c). For the dissolution test (n = 3), the 
remaining height of dissolved microneedles was 199.4 ± 23.3 µm 
(39.9% of full height) and 66.8 ± 2.4 µm (13.4% of full height) after 5 
min (Fig. 11d) and 15 min (Fig. 11e and f) dissolution, respectively 
(Table 3). Compared to the empty dMNAs (without ovalbumin), which 
showed 43.8 µm (8.8% of full height, fabricated via centrifugation 
method) and 58.1 µm (11.6% of full height, fabricated via automatic 
system) of residual height after 5 min dissolution, AF647-ovalbumin 
containing dMNAs displayed slower dissolution. 
Based on the protein concentration (10 mg/mL) and the total volume 
dispensed into the cavities (1.35 µL), the dispensing solution contained 
13.5 µg of ovalbumin. Based on the fluorescence intensity of AF647- 
ovalbumin loaded dMNAs, 13.3 ± 0.15 µg of ovalbumin was loaded in 
the dMNA, which corresponds to a loading efficiency of 98.7 ± 1.11% of 
AF647-ovalbumin. After dissolving the microneedles, the remaining 
Fig. 10. Representative microscopic images of 6.5% (w/v) PVP/PEG dMNAs fabricated with 8 mbar of low-pressure and a PDMS thickness of 4.5 mm. (a and b) To 
ensure air-free microneedle, microneedles were cut horizontally and their cross-sections were imaged by SEM. Rhodamine B dye was added to the 5% (w/v) PVP/ 
PEG solution and its distribution in dMNAs was imaged by using (c) brightfield and (d) fluorescence microscopy. Both images illustrate that the polymer formulation 
with rhodamine B dye is exclusively present in the microneedles. 
Fig. 11. Microscopic images of AF647 labelled ovalbumin loaded microneedles. (a) A microneedle containing AF647 labelled ovalbumin before skin penetration. (b) 
100% skin penetration efficiency (n = 4) indicates that microneedles have sufficient sharpness and mechanical strength. Successful delivery of ovalbumin is revealed 
from (c) the fluorescence in the penetrated skin. Brightfield microscopic images of leftover microneedles after (d) 5 min and (e) 15 min dissolution. Fluorescence 
microscopic image of the remaining microneedle after (f) 15 min dissolution. 
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amount of AF647-ovalbumin in dMNAs was 4.73 ± 0.09 µg. Therefore, 
8.57 µg (13.3–4.73 µg) of AF647-ovalbumin was delivered into the skin. 
After characterizing ovalbumin in dMNA with SDS-PAGE, a single band 
corresponding to ovalbumin was observed at 45 kDa without signals of 
aggregation or fragmentation (data not shown). 
4. Discussion 
In this study, an automatic dMNA fabrication system was engineered, 
and its design procedure was illustrated step by step from the selection 
of a dispenser to the incorporation of stages and the dispenser. Our aim 
was to develop a method to minimize the antigen waste and shorten the 
fabrication time compared to a commonly used centrifugation method. 
Eventually, the automatic fabrication system successfully replaced the 
centrifugation method with decreased required volume of (antigen- 
containing) polymer solution and reduced fabrication time. 
Despite its ease of application, the centrifugation method has a 
critical drawback especially for the scale-up fabrication which is a high 
antigen loss. In order to solve this problem, various approaches have 
been developed to date. The drug solution was loaded only into the 
microneedle tip by removing the excess solution in the base part with a 
spatula (Chen et al., 2019). Another method is the 3D printing technique 
that avoids the presence of antigen in the base part by building up a 
pyramid with a cone shape of microneedles on the substrate followed by 
washing with isopropyl alcohol to remove excess resin (Pere et al., 
2018). Two different layers which were an antigen-containing polymer 
formulation and a blank formulation without antigen were casted so that 
the unnecessary antigen in the backplate layer could be avoided (Zaric 
et al., 2013). Another multi-layers of two different formulations were 
applied by spraying an antigen-containing formulation and a backplate 
formulation (McGrath et al., 2014). All these techniques for the dMNA 
fabrication resulted in a reduction of polymer or/and antigen waste. 
Nevertheless, they still required an additional fabrication step such as 
removal of excess antigen solution and applying an additional layer of 
the formulation. The spray technique also couldn’t avoid the loss of 
antigen as it sprayed not only into the cavities of the microneedle tip but 
also at the surface of the microneedle mould. 
To minimize the antigen waste using a single step fabrication 
method, we developed a precise dispensing method with a nano-droplet 
size dispenser and an accurate positioning of the PDMS mould. In terms 
of using the dispenser and stages, our automatic fabrication system has 
similar aspects, as compared to the system described by Allen et al. 
(Allen et al., 2016). However, a major difference in our approach is that 
we applied low-pressure instead of mould wetting in order to remove 
entrapped air in the microneedle cavities. Therefore, preparing an 
additional formulation for wetting the mould is not necessary and 
fabrication time can be further decreased, as the low-pressure is applied 
during the dispensing process. Further difference are the size of droplet 
and the covered viscosity range. Their Piezo dispensing technology can 
produce smaller droplet as 1–70 pL, however, the viscosity range of 
polymer formulations is lower (<20 mPa.s) than our system (<50 mPa. 
s). This viscosity issue can narrow down the number of dispensable 
polymer formulations. Therefore, the optimal ratios between PVA/ 
trehalose/tween were selected considering viscosity below 20 mPa.s, 
and dMNAs fabricated through incorporated dispenser and stages using 
LabVIEW. LabVIEW can facilitate the system operation for users as it 
displays eidetic view of the system and demand a simple operation 
compared to coding. Their extended study (O’Mahony et al., 2017) also 
shows successful skin penetration and delivery of formulation in the 
human skin with empty dMNAs (without antigen). 
As a result, the automatic fabrication system overcame limitations of 
prior arts by dispensing antigen solution only into the microneedle tip. 
Numerically, the automatic fabrication system showed antigen loading 
efficiencies close to 98.7%, while the conventional process showed 
loading efficiencies of about 0.14%. Consequently, this can lead to a 
dramatic reduction in preparation cost of antigen loaded dMNAs. In 
addition to the economic advantage, this method can easily be scaled up, 
as the dispensing process is executed automatically by programming, 
which makes it attractive for low-cost manufacturing at an industrial 
scale. 
Using the current settings with a concentration of 10 mg/mL oval-
bumin and a 1.35 µL dispensing volume, we could deliver 8.57 µg of 
ovalbumin into the skin. In a previous study, a dose as little as 0.4 µg of 
ovalbumin induced similar level of IgG titers compared to 15 µg of 
ovalbumin administration through intramuscular route (Raphael et al., 
2010). Therefore, we consider the loaded and released amount of 
ovalbumin sufficiently high to induce an immune response. 
To establish a fully automated production process, there are some 
parts of the automatic fabrication system that may be improved. Firstly, 
it is envisaged to develop an optical detection system. The shape of the 
microneedle mould needs to be adjusted, depending on the dosage of 
antigen and the desired radius of the microneedle base (Römgens et al., 
2016). As a different design of moulds requires a different code for the 
alignment of the dispenser with respect to the microneedle cavities, 
developing an optical sensor for detection of microneedle cavities can 
facilitate the alignment without re-writing the code (O’Mahony et al., 
2017). 
Secondly, engineering an additional step for automatic demoulding 
of dMNAs is advantageous. The combination of 8 mbar of low-pressure 
and 4.5 mm of the mould thickness resulted in 97% of intact micro-
needles. The damaged 3% microneedles were mostly from the edge of 
the mould, and the damage mainly occurred during the removal of 
dMNAs from the mould as other studies also reported (Chen et al., 2019; 
Schift et al., 2005). This is because the demoulding step is the most 
delicate part of the whole fabrication process, and the microneedles are 
not precisely vertically removed from the mould. Hence, automatic 
demoulding of dMNAs can lower the number of damaged microneedles 
by applying a vertical ejecting force (Worgull et al., 2008) to dMNAs 
alongside holding the PDMS mould with a sucking or pulling force to the 
other side. 
Lastly, multiple nozzles of the dispenser are necessary to speed up the 
fabrication especially for the industrial scale fabrication. This is true not 
only for the reduction of fabrication time, but also because additional 
nozzles allow to dispense different drug solutions. Therefore, we can 
extend this study to design multilayer dMNAs. By optimizing the vis-
cosity and/or concentration of each polymer/antigen solution and 
layering them into the microneedle cavities, release of each polymer/ 
antigen solution is controllable as desired (Fukushima et al., 2011; Lee 
et al., 2017). 
As another extension of this study, incorporation of the antigen 
encapsulated nanoparticles into dMNAs is ongoing. It has been shown 
that nanoparticles can potentiate the immune response via intradermal 
injection (Cole et al., 2019; Niu et al., 2019). To this end, securing the 
stability and homogeneous distribution of nanoparticles in the micro-
needles is desirable. 
Table 3 
Skin penetration efficiency and remaining height of empty and AF647- 
ovalbumin loaded microneedles (both are fabricated via automatic system). 
AF647-ovalbumin loaded dMNAs displayed the same penetration efficiency 
compared to empty dMNAs. The height of AF647-ovalbumin loaded micro-
needles after 15 min dissolution was higher than that of empty microneedles 
after 5 min dissolution, but there was no significant difference (p > 0.01). The 
data was presented as mean ± SD (n = 4 for penetration efficiency and n = 3 for 





Penetration efficiency (%) 100 ± 0 100 ± 0 
Remaining height after 5 min 
dissolution (µm) 
58.1 ± 3.1 199.4 ± 23.3 
Remaining height after 15 min 
dissolution (µm) 
N/A 66.8 ± 2.4  
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In order to perform additional quality control of dMNAs, more sta-
bility tests of dMNAs are required. For example, storage of dMNAs at 
different humidity and temperature conditions (Chu et al., 2016), fol-
lowed by a skin penetration test can be executed. Also, mechanical 
forces can be applied to dMNAs to determine the fracture force (Pan 
et al., 2018). 
In conclusion, we have engineered an automated system for the 
dMNA fabrication. The selected polymer formulation, 6.5% (w/v) PVP/ 
PEG in PB, with or without antigen, met two critical requirements for the 
resulting dMNAs: sufficient mechanical strength which can penetrate 
the skin and fast dissolution upon administration (<15 min). Moreover, 
using the automatic dMNA fabrication system minimizes antigen loss 
and production time, opening the possibility of low-cost industrial-scale 
production. 
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